Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcin.2023.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early safety after TAVR according to VARC-3 criteria: incidence, predictors, and clinical impact.
Rev Esp Cardiol (Engl Ed)
December 2024
Département de Cardiologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Quebec, Canada. Electronic address:
Introduction And Objectives: The Valve Academic Research Consortium (VARC)-3 definition of the early safety (ES) composite endpoint after transcatheter aortic valve replacement (TAVR) lacks clinical validation. The aim of this study was to determine the incidence, predictors, and clinical impact of ES after TAVR as defined by VARC-3 criteria.
Methods: We performed a multicenter study including 10 078 patients with severe aortic stenosis undergoing transarterial TAVR.
Clinical outcomes of patients with bicuspid aortic valve undergoing a targeted transcatheter aortic valve replacement approach: the LIRA Method.
Can J Cardiol
December 2024
Interventional Cardiology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Interventional Cardiology Division, Ospedale Maggiore, Bologna, Italy; Cardiovascular Imaging Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Background: Transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve (BAV) disease is still burdened by a non-negligible rate of stroke and permanent pacemaker implantation (PPI). These suboptimal results, possibly related to the unique BAV anatomy, might suggest the use of a different sizing method in this setting. The aim of our study is to evaluate whether the application of the supra-annular LIRA method might improve clinical outcomes in this population.
View Article and Find Full Text PDFThe impact of myocardial injury on outcomes in TAVI patients.
Clin Res Cardiol
December 2024
Department of Cardiology and Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, University of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Article Synopsis
- The study investigates the impact of peri-procedural myocardial injury (PPMI) after transcatheter aortic valve implantation (TAVI) using the updated VARC-3 criteria compared to the previous VARC-2 criteria.
- High-sensitivity cardiac troponin T (hs-cTnT) levels were assessed pre- and post-procedure, with elevated baseline levels being significant predictors of all-cause mortality and major cardiac adverse events within one year post-TAVI.
- The findings indicate that VARC-3 criteria offered better prognostic insights regarding patient outcomes, with patients meeting VARC-3 criteria experiencing higher mortality rates than those meeting VARC-2 criteria.
Peri-procedural outcome according to VARC-3 criteria and hemodynamic mid-term follow-up after Valve-in-valve transcatheter aortic valve replacement for failed aortic bioprosthesis.
Cardiovasc Interv Ther
January 2025
Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan.
Despite the widespread adoption of valve-in-valve transcatheter aortic valve replacement (VIV-TAVR) for patients with failed aortic bioprosthesis, the effectiveness of this treatment for Japanese patients frequently associated with small aortic annuli remains unclear. From December-2011 to October-2022, 41 consecutive patients undergoing VIV-TAVR were enrolled in this study. The endpoints were technical success, device success, early safety, and two-year mortality according to implanted surgical valve size (small valves: 19-mm and 21-mm, n = 23; large valves: 23-mm and 25-mm, n = 18).
View Article and Find Full Text PDFTAVI with the ACURATE neo2 in severe bicuspid aortic valve stenosis: the Neo2 BAV Registry.
EuroIntervention
November 2024
Galway University Hospital, Galway, Ireland.
Background: The ACURATE neo2 is a contemporary transcatheter aortic valve implantation (TAVI) system approved for the treatment of severe aortic stenosis in Europe. The ACURATE neo2 has not been evaluated in bicuspid aortic valve (BAV) stenosis.
Aims: We sought to evaluate the safety and efficacy of ACURATE neo2 in patients with BAV stenosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!